Mesa, R. A., Masarova, L., Reeves, B., Xiao, Z., Qin, A., Gill, H., Jin, J., Komatsu, N., Kirito, K., Chaer, F. E., Foltz, L. M., Tashi, T., Zeinah, G. F. A., Shih, L., Maze, D., Oh, S., Zagrijtschuk, O., Sato, T., Yacoub, A., Mascarenhas, J. (2026). Integrated analysis of the ropeginterferon alfa-2b clinical program in essential thrombocythemia to demonstrate molecular and hematologic responses with safety profile information across treatment lines, ethnicities, and driver mutation types.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6576